To control antibody mediated rejection following kidney and liver transplantation in ABO-incompatible, donor specific antibody positive patients by using rituximab, proteasome inhibitor, complement inhibitor, and immunoglobulin administratio
Not Applicable
- Conditions
- Antibody mediated rejection
- Registration Number
- JPRN-UMIN000023064
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Cases who has allergic reaction against relevant drugs.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Judging improvements of clinical (Cr, AST, ALT, T-Bil etc.) and pathological findings(Banff 2013 criteria) at day 1, 3, 5, 7, 14, 28, and during a follow-up period following administration.
- Secondary Outcome Measures
Name Time Method